Breaking Down Exelixis: 7 Analysts Share Their Views
Portfolio Pulse from Benzinga Insights
Exelixis (NASDAQ:EXEL) has been analyzed by 7 analysts, showing a range of opinions from bullish to bearish. The average 12-month price target is $26.57, up 15.52% from the previous $23.00. Analyst actions include ratings from 'Overweight' to 'Equal-Weight' and price target changes, with the highest target being $31.00. Exelixis is a biopharmaceutical company with a lead molecule, cabozantinib, for cancer treatment. Financially, Exelixis has a market cap below industry average, a revenue growth of 14.62%, a net margin of 0.22%, an ROE of 0.04%, an ROA of 0.03%, and a low debt-to-equity ratio of 0.08.
January 30, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Exelixis has received varied analyst ratings with an increased average price target of $26.57. The company's financial indicators show strong performance, which may positively influence investor sentiment.
The increase in the average price target suggests analysts are optimistic about Exelixis's future performance. The company's strong financial metrics, such as revenue growth and profitability, support this view. The positive analyst ratings and upward revision in price targets are likely to have a favorable short-term impact on EXEL's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100